Hims spent 2024–2025 as one of the biggest compounded-semaglutide sellers in the US. The pricing was aggressive enough to draw a public confrontation with Novo Nordisk. On February 5, 2026, Hims announced a $49 compounded semaglutide pill option. Novo Nordisk's leadership criticized the move and signaled legal action. The two companies settled on March 9, 2026, and Hims quietly exited compounded semaglutide for new patients. The platform is now a branded-only GLP-1 service offering Wegovy, oral Wegovy, and Zepbound — at premium prices that include a $149/month membership.
Direct answer: As of May 2026, Hims sells branded Wegovy injection ($299/month self-pay), oral Wegovy pill ($249/month), and Zepbound injection ($399/month), behind a $39 first-month membership that auto-renews at $149/month. With commercial insurance and the Novo Nordisk copay assistance card, monthly cost can drop to $0–$25. Compounded semaglutide was wound down after the Novo settlement; full exit completes by mid-2026. The clinical model is text-only messaging — no video, no required labs, no obesity-medicine specialists. Best for tech-comfortable adults who want fast, branded GLP-1 access; less appropriate for complex medical histories.
Current Lineup (May 2026)
| Medication | Hims self-pay price | Form | Frequency |
|---|---|---|---|
| Wegovy (semaglutide injection) | $299/month | Weekly subQ | Once weekly |
| Wegovy HD 7.2 mg | $299/month | Weekly subQ | Once weekly |
| Oral Wegovy (semaglutide pill) | $249/month | Daily tablet | Daily |
| Zepbound (tirzepatide injection) | $399/month | Weekly subQ | Once weekly |
Membership fee: $39 for month 1, auto-renews at $149/month.
What Happened in 2025–2026
A condensed timeline of the Hims GLP-1 saga:
| Date | Event |
|---|---|
| 2023–2024 | Hims grows rapidly selling compounded semaglutide during FDA shortage |
| February 2025 | FDA resolves semaglutide shortage; compounding rules tighten |
| May 2025 | FDA ends grace period for mass-compounded GLP-1s |
| September 2025 | FDA issues warning letters to ~55 telehealth companies, including Hims, over compounded GLP-1 marketing |
| February 5, 2026 | Hims announces $49 compounded semaglutide pill option |
| February 5, 2026 | Novo Nordisk leadership publicly criticizes the move, signals legal action |
| March 9, 2026 | Hims settles with Novo Nordisk |
| March 2026+ | Hims becomes authorized telehealth provider for branded Wegovy and oral Wegovy |
| Mid-2026 | Compounded semaglutide for new patients fully wound down |
Translation: the $99 (and briefly, $49) compounded semaglutide era at Hims is over for new patients. The platform now sells the same FDA-approved drugs anyone else can buy, with a telehealth wrapper.
What the $149/Month Membership Includes
- Asynchronous messaging with licensed clinicians (no video calls)
- Eligibility evaluation for weight-loss prescription
- Insurance benefit checks for Wegovy, oral Wegovy, and Zepbound coverage
- Manufacturer savings card setup for commercially insured patients
- Dose adjustments and side-effect management via in-app messaging
- Optional add-ons: nausea support, B-vitamin shots, behavioral coaching
What it does not include:
- Video consultations (everything is text-based)
- Baseline labs ordered before prescribing — Hims does not require or order labs
- Obesity medicine specialists — clinicians are general telehealth providers
- 24/7 phone access for emergencies
That last point matters. Many physicians consider lab work before starting GLP-1 standard of care, especially for patients with diabetes, kidney disease, or thyroid concerns.
Real Cost Scenarios
| Scenario | Monthly out-of-pocket |
|---|---|
| Commercial insurance covers Wegovy + savings card | $0–$25 medication + $149 membership = $149–$174 |
| Self-pay Wegovy injection | $299 + $149 = $448 |
| Self-pay oral Wegovy | $249 + $149 = $398 |
| Self-pay Zepbound | $399 + $149 = $548 |
| Medicare with diabetes indication | Variable; often covered, but $149 membership remains |
These add up to $1,800–$6,600/year depending on coverage.
Where Hims Sits vs Competitors
| Provider | Compounded sema? | Branded Wegovy/Zepbound? | Typical total monthly cost |
|---|---|---|---|
| Hims (post-settlement) | No (new patients) | Yes | $149–$548 |
| Ro | No (new patients) | Yes | $145–$494 |
| Henry Meds | Yes | No | $129–$249 (all-in) |
| Mochi | Yes (some) | Yes | $135–$399 |
| Sequence (WeightWatchers Clinic) | No | Yes | $99 + drug cost |
| Eden | Yes | Limited | $149–$329 |
Strengths
- Smooth digital experience — onboarding, refills, messaging are polished
- Authorized provider for branded GLP-1s — accessible without changing primary care
- Savings card integration — gets some patients to $25/month for medication
- Branded medication — same drug as the pharmacy, full label and traceability
- Side-effect management in-app — nausea support, dose pauses
Weaknesses
- $149/month membership on top of medication — real cost penalty vs going through a regular doctor
- No more compounded option for new patients — the cheap entry point is gone
- Self-pay is expensive vs other telehealth options
- Text-only model — no video calls, harder for complex situations
- No baseline labs — below standard practice for chronic prescriptions
- No obesity medicine specialists — clinicians are generalists
- Not available in all 50 states — eligibility varies by jurisdiction
- Auto-renew membership — easy to forget about; harder to cancel than expected
Who Hims Works Well For
- Adults who want fast online onboarding to a branded GLP-1
- Patients with commercial insurance who want savings-card integration handled
- People who dislike going to a clinic and would otherwise not start treatment
- Tech-comfortable users who prefer in-app messaging over phone calls
Who Should Look Elsewhere
- Patients with complex medical history needing a specialist
- People on Medicare or Medicaid for whom the membership is unnecessary
- Patients seeking the cheapest possible compounded option — Henry Meds and Mochi are now cheaper
- Anyone whose primary care doctor will prescribe and bill insurance directly
- Patients with kidney disease, prior pancreatitis, or thyroid history who want pre-screening labs
How To Cancel If You Want To
Hims memberships auto-renew. To cancel:
- Log in to the Hims account dashboard
- Go to Account → Subscription
- Click Manage Subscription
- Select Cancel
Cancellation is typically effective at the end of the current billing period. Confirmation email arrives within hours. If you don't see it: contact support — some users report needing to follow up explicitly.
What People Get Wrong About Hims GLP-1
- "Hims is still the cheapest GLP-1 option." Not since the Novo settlement. Henry Meds and Mochi are now cheaper for compounded; Sequence is cheaper for branded with insurance.
- "It's just like buying from a pharmacy." It is — with an extra $149/month membership.
- "The compounded version is still available." Only to a small group of grandfathered existing patients, being phased out by mid-2026.
- "All Hims products are interchangeable with brand-name drugs." The branded products are the same as anywhere else; what differs is the channel and pricing.
- "They check my labs first." They don't, by default.
Frequently Asked Questions
Does Hims still sell compounded semaglutide? Not to new patients as of March 9, 2026. The full exit from compounded semaglutide is expected by mid-2026.
How much is Hims GLP-1 per month? $299/month self-pay for Wegovy injection, $249 for oral Wegovy, $399 for Zepbound — plus a $149/month membership fee. Insurance with the Novo Nordisk copay card can reduce medication cost to $0–$25.
Is Hims a real prescription? Yes. Hims connects users with licensed clinicians who write real prescriptions for FDA-approved GLP-1 medications.
Does Hims order labs before prescribing GLP-1? No. Hims does not require or order baseline labs, which is below standard care for many physicians.
Is Hims available in all 50 states? No. GLP-1 treatment options are not currently available in all 50 states; availability varies by jurisdiction.
Does insurance work with Hims? Yes — Hims helps run benefit checks and apply manufacturer savings cards. Coverage outcomes vary by plan.
How does Hims compare to Ro for GLP-1? Both moved largely to branded GLP-1s in 2026. Pricing is similar; user experience is the main differentiator.
What happened with the $49 pill announcement? Hims announced $49 compounded semaglutide on February 5, 2026. Novo Nordisk threatened legal action. The two parties settled on March 9, 2026, and Hims discontinued compounding for new patients.
Last reviewed: May 13, 2026
